Rice Hall James & Associates LLC Has $4.75 Million Stake in ADMA Biologics Inc $ADMA

Rice Hall James & Associates LLC cut its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 17.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 323,653 shares of the biotechnology company’s stock after selling 66,962 shares during the quarter. Rice Hall James & Associates LLC owned about 0.14% of ADMA Biologics worth $4,745,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in ADMA. Cullen Frost Bankers Inc. boosted its position in ADMA Biologics by 112.5% during the second quarter. Cullen Frost Bankers Inc. now owns 2,042 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 1,081 shares during the period. Toth Financial Advisory Corp raised its holdings in ADMA Biologics by 1,081.6% in the 2nd quarter. Toth Financial Advisory Corp now owns 2,505 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 2,293 shares during the period. Ameritas Advisory Services LLC acquired a new stake in ADMA Biologics during the second quarter worth approximately $46,000. Smartleaf Asset Management LLC boosted its holdings in shares of ADMA Biologics by 161.4% during the first quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company’s stock worth $49,000 after acquiring an additional 1,493 shares during the period. Finally, Blue Trust Inc. grew its position in shares of ADMA Biologics by 53.6% in the second quarter. Blue Trust Inc. now owns 2,762 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 964 shares during the last quarter. Institutional investors own 75.68% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $28.50.

ADMA Biologics Trading Down 1.3%

NASDAQ:ADMA opened at $19.28 on Friday. ADMA Biologics Inc has a 52 week low of $13.50 and a 52 week high of $25.67. The firm’s fifty day moving average is $17.43 and its 200-day moving average is $17.23. The firm has a market cap of $4.59 billion, a P/E ratio of 22.42 and a beta of 0.43. The company has a debt-to-equity ratio of 0.18, a quick ratio of 3.65 and a current ratio of 7.13.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, November 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.16. ADMA Biologics had a net margin of 42.87% and a return on equity of 36.52%. The business had revenue of $134.22 million for the quarter, compared to analyst estimates of $131.20 million. During the same quarter in the previous year, the business earned $0.15 earnings per share. ADMA Biologics’s revenue for the quarter was up 12.0% on a year-over-year basis. Equities analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.